BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26611598)

  • 41. Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo.
    Sakaguchi DS
    Methods Mol Biol; 2019; 1940():143-155. PubMed ID: 30788823
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of neurotrophic factors in limb and extraocular muscles of mouse model of amyotrophic lateral sclerosis.
    Harandi VM; Lindquist S; Kolan SS; Brännström T; Liu JX
    PLoS One; 2014; 9(10):e109833. PubMed ID: 25334047
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice.
    Kim H; Kim HY; Choi MR; Hwang S; Nam KH; Kim HC; Han JS; Kim KS; Yoon HS; Kim SH
    Neurosci Lett; 2010 Jan; 468(3):190-4. PubMed ID: 19879334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury.
    Cheng FC; Tai MH; Sheu ML; Chen CJ; Yang DY; Su HL; Ho SP; Lai SZ; Pan HC
    J Neurosurg; 2010 Apr; 112(4):868-79. PubMed ID: 19817545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.
    Khoo ML; Tao H; Meedeniya AC; Mackay-Sim A; Ma DD
    PLoS One; 2011; 6(5):e19025. PubMed ID: 21625433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis.
    Brambilla L; Guidotti G; Martorana F; Iyer AM; Aronica E; Valori CF; Rossi D
    Hum Mol Genet; 2016 Jul; 25(14):3080-3095. PubMed ID: 27288458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice.
    Dodge JC; Treleaven CM; Fidler JA; Hester M; Haidet A; Handy C; Rao M; Eagle A; Matthews JC; Taksir TV; Cheng SH; Shihabuddin LS; Kaspar BK
    Mol Ther; 2010 Dec; 18(12):2075-84. PubMed ID: 20859261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene and protein therapies utilizing VEGF for ALS.
    Keifer OP; O'Connor DM; Boulis NM
    Pharmacol Ther; 2014 Mar; 141(3):261-71. PubMed ID: 24177067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice.
    Bordet T; Lesbordes JC; Rouhani S; Castelnau-Ptakhine L; Schmalbruch H; Haase G; Kahn A
    Hum Mol Genet; 2001 Sep; 10(18):1925-33. PubMed ID: 11555629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis.
    Vercelli A; Mereuta OM; Garbossa D; Muraca G; Mareschi K; Rustichelli D; Ferrero I; Mazzini L; Madon E; Fagioli F
    Neurobiol Dis; 2008 Sep; 31(3):395-405. PubMed ID: 18586098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of the efficiency of gene-cell therapy in transgenic mice with amyotrophic lateral sclerosis phenotype.
    Mukhamedyarov MA; Rizvanov AA; Safiullov ZZ; Izmailov AA; Sharifullina GA; Solovieva VV; Fedotova VY; Salafutdinov II; Cherenkova EE; Bashirov FV; Kaligin MS; Abdulkhakov SR; Shmarov MM; Logunov DY; Naroditsky BS; Kiyasov AP; Zefirov AL; Islamov RR
    Bull Exp Biol Med; 2013 Feb; 154(4):558-61. PubMed ID: 23486603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?
    Iłzecka J
    Curr Opin Investig Drugs; 2006 Jan; 7(1):54-9. PubMed ID: 16425672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain.
    Moloney TC; Rooney GE; Barry FP; Howard L; Dowd E
    Brain Res; 2010 Nov; 1359():33-43. PubMed ID: 20732313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model.
    Pastor D; Viso-León MC; Jones J; Jaramillo-Merchán J; Toledo-Aral JJ; Moraleda JM; Martínez S
    Stem Cell Rev Rep; 2012 Jun; 8(2):445-58. PubMed ID: 21717132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.
    Lambrechts D; Carmeliet P
    Biochim Biophys Acta; 2006; 1762(11-12):1109-21. PubMed ID: 16784838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pilot study of cell-mediated gene therapy for spinal cord injury in mini pigs.
    Islamov RR; Sokolov ME; Bashirov FV; Fadeev FO; Shmarov MM; Naroditskiy BS; Povysheva TV; Shaymardanova GF; Yakupov RA; Chelyshev YA; Lavrov IA
    Neurosci Lett; 2017 Mar; 644():67-75. PubMed ID: 28213069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients.
    Aebischer P; Schluep M; Déglon N; Joseph JM; Hirt L; Heyd B; Goddard M; Hammang JP; Zurn AD; Kato AC; Regli F; Baetge EE
    Nat Med; 1996 Jun; 2(6):696-9. PubMed ID: 8640564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
    Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
    Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice.
    Rizvanov AA; Guseva DS; Salafutdinov II; Kudryashova NV; Bashirov FV; Kiyasov AP; Yalvaç ME; Gazizov IM; Kaligin MS; Sahin F; Mukhamedyarov MA; Palotás A; Islamov RR
    Exp Biol Med (Maywood); 2011 Jan; 236(1):91-8. PubMed ID: 21163822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia.
    Toyama K; Honmou O; Harada K; Suzuki J; Houkin K; Hamada H; Kocsis JD
    Exp Neurol; 2009 Mar; 216(1):47-55. PubMed ID: 19094989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.